Proactive Investors - Run By Investors For Investors

Sirona Biochem to test skin lightening product at higher doses to boost effectiveness

Sirona’s shares have been on a tear over the past few months, rising over 640% since the beginning of the year
A woman looking into a mirror
TFC-1067 is used to lighten dark spots on the skin

Sirona Biochem Corp (CVE:SBM) announced Tuesday that it is planning to test its skin lightening product at higher doses to improve its efficacy.

The product, TFC-1067, will be tested at a concentration three times higher than what was used in a previous clinical trial, the drug company said in a statement. Higher dosing is expected to increase the effectiveness of the product as well as work more quickly than the previously established dose.

Vancouver-based Sirona’s shares have been on a tear over the past few months, rising over 640% to $0.52 from $0.08 since the start of the year. However, shares were were trading 11.9% lower Tuesday midday at C$0.52 on a broad market pullback. 

READ: SkinBioTherapeutics chief "really pleased" with human trial data for new skin cream

Currently TFC-1067 is being tested in standard in vitro procedures, but Sirona’s consultant safety assessor CEHTRA has recommended further testing at the higher dose, the company said in a statement.

The higher doses will be assessed by cosmetic testing company Idea Lab. If results continue to show no evidence of skin irritation, Sirona will begin human clinical trials.

"The clinical effect of TFC-1067 to lessen dark spots or have an overall brightening effect is largely dose dependent,” said Sirona Biochem CEO Howard Verrico. "We anticipate TFC-1067 will be used at higher doses without adverse effects. While we are pleased with the excellent clinical results achieved so far, being able to test at significantly higher concentrations will likely lead to better clinical effectiveness, potentially faster results and a better range of consumer dosing options."

The new development is of “substantial commercial interest” to potential cosmetic partners in North America and China, the company said in a statement. According to data cited by Sirona, the global skin lightening market is expected to be valued at over US$30 billion within the next five years.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

 

View full SBM profile View Profile

Sirona Biochem Timeline

Related Articles

Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
patch
May 20 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use